SB 204990

Cat. No. 4962 6 篇引用文献提交评论说明书 / 分析证书（CoA） / 化学品安全技术说明书（SDS）

Pricing	Availability		Qty

说明： ATP citrate lyase (ACLY) inhibitor

化学名： (3R,5S)-rel-5-[6-(2,4-Dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid

纯度： ≥98% (HPLC)

引用文献 (6)

生物活性技术数据溶解性计算器说明书参考文献

生物活性 for SB 204990

SB 204990 is an ATP citrate lyase (ACLY) inhibitor; it is a prodrug of SB 201076. SB 204990 inhibits cholesterol and fatty acid synthesis in a dose-dependent manner in HepG2 cells. Suppresses growth of cancer cells showing aerobic glycolysis in vitro and in vivo. Orally active.

许可信息

Sold for research purposes under agreement from GlaxoSmithKline

化合物库 for SB 204990

SB 204990 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。

技术数据 for SB 204990

分子量	389.27
公式	C₁₈H₂₂Cl₂O₅
储存	Store at -20°C
纯度	≥98% (HPLC)
CAS Number	154566-12-8
PubChem ID	10340264
InChI Key	YTRNLFYTHYWDAU-KDOFPFPSSA-N
Smiles	ClC(C=C(Cl)C=C2)=C2CCCCCC[C@@H](OC1=O)C[C@]1(O)CC(O)=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for SB 204990

	溶剂	最高浓度 mg/mL	最高浓度 mM
溶解性
	DMSO	38.93	100
	ethanol	38.93	100

制备储备液 for SB 204990

以下数据基于产品分子量 389.27。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

浓度/溶剂体积/质量	1 mg	5 mg	10 mg
1 mM	2.57 mL	12.84 mL	25.69 mL
5 mM	0.51 mL	2.57 mL	5.14 mL
10 mM	0.26 mL	1.28 mL	2.57 mL
50 mM	0.05 mL	0.26 mL	0.51 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

产品说明书 for SB 204990

分析证书/产品说明书

化学品安全技术说明书

参考文献 for SB 204990

参考文献是支持产品生物活性的出版物。

Pearce et al (1998) The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem.J. 334 113 PMID: 9693110

Gribble et al (1998) ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R*,5S*)-ω-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzy J.Med.Chem. 41 3582 PMID: 9733484

Hatzivassiliou et al (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8 311 PMID: 16226706

If you know of a relevant reference for SB 204990, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 ATP Citrate Lyase Inhibitors

关键词: SB 204990, SB 204990 supplier, SB204990, ATP-citrate, lyases, ACL, inhibitors, inhibits, prodrug, SB-201076, cholesterol, fatty, acid, metabolic, lipids, synthases, transferases, ACLY, ATP, Citrate, Lyase, 4962, Tocris Bioscience